The Nordic AML Group (NAMLG) aim to foster excellence in research and clinical care in acute myeloid leukemia (AML) in the Nordic countries, by forming an active network of clinicians and basic and translational scientists with deep interest and experience in the field.
Photo: NASA
[News? Please, let us know via namlgewg@gmail.com.]
Results from the Finnish VenEx trial (NCT04267081) have now been published in Blood. You can find the publication by using this link.
NAMLG arranged a webinar 2024-09-24 on the topic “Aza-Ven: recent clinical updates”.
You can find a recording of the webinar using this link.
[Have an event? Please, let us know via namlgewg@gmail.com.]
This Servier arranged webinar is for hematologists. The agenda for the webinar is: 12:00-12:05 – Introduction by Erik Holgén, Product Manager, Servier 12:05-12:30 – Prof. Dr. Michael Heuser - Will […]
Find out more »MNSCT 2024 Meeting Date: 21 November 2024 Venue: Grand Hotel, Lund, Sweden or online Registration: https://mkon.nu/mnsct_2024/registration Program 12:00-12:55 Lunch, registration starts at 11.45 13:00-13:05 Welcome/Introduction (Assoc. Prof. Andreas Björklund, Stockholm, Assoc. Prof. Jörg Cammenga, Lund) Session […]
Find out more »The Educational Working Group is planning an "AML Course Day" in conjunction with the Nordic AML Meeting in Bergen 2025. The AML Course Day covers topics such as the current […]
Find out more »Save the dates for the upcoming Nordic AML Meeting in Bergen, Norway, 2025.
Find out more »Click here to add your own text
